<DOC>
	<DOC>NCT02231255</DOC>
	<brief_summary>Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions</brief_summary>
	<brief_title>Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients with Idiopathic Parkinson's disease who are planned to undergo a switch from another dopamine agonist to Sifrol® Neurologists and psychiatrists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>